TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21349747
Drug: Anti-hypertensive drugs
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-hypertensive drugs
Study: 15026849
Drug: Data mining
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data mining methods for predicting IVS thickness clusters ('small' or 'large') using a clusterbase/rulebase combination.
Study: 11297240
Drug: Edatrexate 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edatrexate 40 mg/m2 weekly with cisplatin 120 mg/m2 every 4 weeks (Schedule A)
Study: 26080804
Drug: Almond consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almond consumption (85 g/day) added to a National Cholesterol Education Program (NCEP) Step 1 diet (ALM) for 6 weeks
Study: 31471313
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg/day
Study: 17076604
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg 1 hour before surgery and 12 hours after the first dose
Study: 17076604
Drug: Dexamethasone 4
Normalized name: dexamethasone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 4 mg 1 hour before surgery and 8 hours after the first dose
Study: 14756620
Drug: Cognitive-behavioral self-help
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral self-help treatment
Study: 364037
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D dietary supplement
Study: 30909946
Drug: Starting antiplatelet
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting antiplatelet therapy
Study: 28756569
Drug: Intratympanic corticosteroids
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic corticosteroids (administered three times every other day)
Study: 25274428
Drug: MPH-MLR 80
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MPH-MLR 80 mg once daily
Study: 25274428
Drug: IR methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR methylphenidate 25 mg three times daily
Study: 22342396
Drug: 3-day albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-day albendazole therapy
Study: 22342396
Drug: 15-day albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15-day albendazole therapy
Study: 22342396
Drug: Albendazole therapy
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole therapy (both durations)
Study: 15623768
Drug: Full treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full treatment with glasses and occlusion
Study: 10197852
Drug: 12-week course
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week course of 300 mg of cyproterone acetate daily followed by surgery (CPA)
Study: 24953249
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical nerve stimulation (TENS) for 60 minutes before 30 minutes of physical therapy
Study: 24953249
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with 30 minutes of physical therapy alone
Study: 19454639
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) alone during maintenance
Study: 19454639
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) plus zolpidem during maintenance
Study: 15219195
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (STEMI patients treated by PTCA without GPIIb-IIIa antagonist)
Study: 12217810
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose anti-thymocyte globulin (ATG) as first-line treatment within 14 days of diagnosis
Study: 12217810
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose anti-thymocyte globulin (ATG) as second-line therapy more than 14 days after diagnosis
Study: 12217810
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose anti-thymocyte globulin (ATG) late treatment group
Study: 12217810
Drug: Concurrent control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent control group (not treated with ATG)
Study: 10354716
Drug: Corticosteroids treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids treatment in patients with idiopathic pulmonary fibrosis and avian fancier's lung
Study: 10354716
Drug: Corticosteroids treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids treatment in sarcoidosis patients
Study: 10354716
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment in pulmonary fibrosis patients
Study: 10354716
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment in sarcoidosis patients
Study: 10354716
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment in avian fancier's lung patients
Study: 10499883
Drug: Repaglinide 1
Normalized name: repaglinide 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide 1 mg before each meal
Study: 668784
Drug: Oral chlordiazepoxide
Normalized name: Chlordiazepoxide
DrugBank: Chlordiazepoxide (DB00475)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral chlordiazepoxide hydrochloride (50 mg)
Study: 22105254
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (75 micrograms)
Study: 9416950
Drug: Enalapril (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (up to 40 mg)
Study: 8387087
Drug: Oral instructions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral instructions indicating no change in blood pressure
Study: 3030946
Drug: Trimethoprim-polymyxin B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-polymyxin B sulfate cream
Study: 16686722
Drug: Solifenacin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin (5 mg)
Study: 20805450
Drug: Multivitamin use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin use during adjuvant chemotherapy
Study: 20805450
Drug: Multivitamin use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin use reported 6 months after completion of adjuvant chemotherapy
Study: 16203942
Drug: Lifestyle-focused, fitness-oriented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle-focused, fitness-oriented gym classes (treatment group)
Study: 7491818
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with Mycobacterium w vaccine
Study: 2110437
Drug: Fleroxacin 200
Normalized name: fleroxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 200 mg for 10 days
Study: 2110437
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg for 10 days
Study: 2110437
Drug: Fleroxacin 600
Normalized name: fleroxacin
DrugBank: Fleroxacin (DB04576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 600 mg for 10 days
Study: 3001664
Drug: d-amphetamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (10 mg)
Study: 1147869
Drug: placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (no drug)
Study: 31600243
Drug: Oral B-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral B-12 2μg/day with multiple micronutrients (UNIMAPP formula + 20gm milk powder)
Study: 21921362
Drug: Vildagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (50 mg/day for 8 weeks, titrated to a maximum of 100 mg/day)
Study: 21921362
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no vildagliptin administered)
Study: 8427432
Drug: Midazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (1 mg/mL) administered until desired sedation achieved (max 5 mL)
Study: 8427432
Drug: Diazepam (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (2.5 mg/mL) administered until desired sedation achieved (max 5 mL)
Study: 3116290
Drug: Intravenous branched
Normalized name: Machilus thunbergii branch extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous branched chain amino acid (BCAA) diet (60-80 g/day, BCAA content 51%, energy 2000 kcal/day)
Study: 3116290
Drug: Nasogastric (NG)
Normalized name: NG
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasogastric (NG) branched chain amino acid (BCAA) diet (amino acids 58 g, BCAA 43%, oligopeptides 19.5 g, energy 2000 kcal/day)
Study: 27647071
Drug: rhGM‐CSF gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGM‐CSF gel
Study: 25759404
Drug: Tianeptine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianeptine (12.5 mg)
Study: 2890364
Drug: Tubocurarine 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tubocurarine 0.05 mg kg‐1
Study: 2890364
Drug: Vecuronium 0.012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.012 mg kg‐1
Study: 27436226
Drug: Self-expansion during
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-expansion during treatment
Study: 17267927
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g eicosapentaenoic acid plus 0.9 g decosahexaenoic acid (n=22)
Study: 15078794
Drug: ML PENTA
Normalized name: 1 ML pentazocine 30 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML PENTA stent
Study: 10855739
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 8-16 mg once daily
Study: 3128139
Drug: Ro 15‐1788
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15‐1788 at a dosage of 0.2 mg (2 ml)
Study: 24429540
Drug: Crystalline amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalline amino acid mixture with protein intakes of 0.1, 0.3, 0.6, 0.9, 1.2, 1.5, or 1.8 g · kg⁻¹ · d⁻¹
Study: 18477493
Drug: Mifepristone tablet
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mifepristone tablet (75 mg)
Study: 10915400
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V suspension 13.3 mg/kg three times daily for 10 days
Study: 1686562
Drug: GR122311X 196
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR122311X 196 mg b.d.
Study: 1686562
Drug: GR122311X 391
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR122311X 391 mg b.d.
Study: 1686562
Drug: GR122311X 782
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR122311X 782 mg b.d.
Study: 8218755
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ranitidine b.d.
Study: 6662004
Drug: Indomethacin 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 0.5% solution eyedrops
Study: 27164985
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg for 3 days prior to surgery (including the day of surgery)
Study: 24360571
Drug: peginterferon α‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon α‐2a + RBV 1600 mg/day + epoetin β (B2; n=13)
Study: 20461765
Drug: Gemcitabine 175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 175 mg/m(2) on days 1, 5, 29, and 33, cisplatin 20 mg/m(2) on days 1‐5 and 29‐32, 5‐FU 600 mg/m(2) on days 1‐5 and 29‐32, followed by radiation with continuous infusion 5‐FU 225 mg/m(2) for 6 weeks
Study: 16133138
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C with atypical antipsychotics
Study: 16133138
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with atypical antipsychotics
Study: 12924045
Drug: Chemoradiotherapy (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (50 to 60 Gy of radiotherapy plus concurrent chemotherapy with 5-fluorouracil (5-FU) plus cisplatin)
Study: 10229251
Drug: Additional preparatory
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional preparatory measures (dietary restrictions and phospho-soda oral saline laxative)
Study: 1867076
Drug: Indomethacin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.2 mg/kg body weight infused over 5 min)
Study: 27619750
Drug: Evolocumab (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (420 mg, monthly subcutaneous)
Study: 11110009
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg, 100 mg, or 200 mg)
Study: 21715446
Drug: Conventional heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional heart failure treatment
Study: 28028768
Drug: Betaine HCl
Normalized name: betaine HCl
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaine HCl (1500 mg) after rabeprazole pretreatment
Study: 22654431
Drug: Rabeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (20 mg twice daily)
Study: 26589718
Drug: Individual completeness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual completeness of chemotherapy rate
Study: 20467406
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) injections (average molecular weight 1.5 million Da), 3 injections at weeks 1, 2, and 3
Study: 18384679
Drug: Etoricoxib 60
Normalized name: etoricoxib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 60 mg daily
Study: 16005691
Drug: Coreg from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coreg from Roche Químicos e Farmacêuticos S.A standard reference formulation
Study: 1720828
Drug: Ro 42‐5892
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 42‐5892 (10‐min infusion, doses ranging from 0.001 to 1 mg/kg)
Study: 1720828
Drug: Ro 42‐5892
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 42‐5892 (100, 600, or 1,200 mg p.o.)
Study: 1720828
Drug: Ro 42‐5892
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 42‐5892 (1,200 mg p.o.)
Study: 6758833
Drug: Prednisone 30
Normalized name: prednisone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 30 mg daily given orally for two weeks
Study: 8806338
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug therapy (Control)
Study: 24216721
Drug: Probucol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (500 mg/day) and cilostazol (200 mg/day) with behavioral modifications
Study: 24216721
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg/day) with behavioral modifications (control group)
Study: 24216721
Drug: Probucol and
Normalized name: Probucol
DrugBank: Probucol (DB01599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probucol and cilostazol treatment
Study: 17392464
Drug: No patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: No patch (matched nonsmokers)
Study: 15971426
Drug: Air-steroid-saline mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air-steroid-saline mixture as contrast medium
Study: 10637949
Drug: Randomised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised treatment within 6 hours
Study: 7737560
Drug: Omeprazole, 20
Normalized name: Omeprazole, 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 20 mg daily for one week
Study: 25808572
Drug: Lornoxicam 8
Normalized name: lornoxicam 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 8 mg
Study: 2036277
Drug: Lornoxicam 2
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 2 mg
Study: 7665721
Drug: Lornoxicam 4
Normalized name: lornoxicam 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 4 mg
Study: 29982720
Drug: Treatment adjustment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment adjustment not in agreement with TTT strategy
Study: 26642907
Drug: Pharmacogenetic-guided warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenetic-guided warfarin dosing algorithm
Study: 12631126
Drug: Eprosartan (E)
DrugBank: Eprosartan (DB00876)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eprosartan (E) 600 mg/day PO for seven days
Study: 9032777
Drug: 0.03 mg/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg/kg/h cortisol infusion
Study: 9032777
Drug: 0.06 mg/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 mg/kg/h cortisol infusion
Study: 9032777
Drug: Placebo condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo condition (placebo tablets and normal saline infusion)
Study: 27687343
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of remifentanil (HR) group
Study: 8942357
Drug: High-energy-protein supplement
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy-protein supplement given immediately after rehydration
Study: 8942357
Drug: High-energy-protein supplement
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy-protein supplement given 2 weeks after presentation
Study: 2057036
Drug: 16-hour nicotine
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16-hour nicotine patch (15 +/- 3.5 mg of nicotine in 16 hours)
Study: 3914473
Drug: Cefotaxime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (1 gram preoperative dose)
Study: 3914473
Drug: Cefoxitin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (2 gram preoperative dose and four 2 gram postoperative doses)
Study: 10695838
Drug: Psychopharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychopharmacological treatment
Study: 22344555
Drug: Pidotimod 800
Normalized name: pidotimod
DrugBank: Pidotimod (DB11364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidotimod 800 mg
Study: 16185216
Drug: Five-Day Plan
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Five-Day Plan (FDP) - a behavioural group-based treatment programme involving five consecutive evening sessions.
Study: 18547294
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg.kg(‐1))
Study: 1671795
Drug: Retinol palmitate
Normalized name: Retinol palmitate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinol palmitate (300,000 IU daily for at least 12 months)
Study: 6361986
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 50-100 mg/kg/day
Study: 26390335
Drug: Mindfulness-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based therapy for insomnia (MBTI)
Study: 17617790
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI)
Study: 23991670
Drug: GW870086 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW870086 (1 mg, once-daily)
Study: 21632199
Drug: Treatment setting
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment setting control
Study: 18501783
Drug: Fenofibrate (160-mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (160-mg/d tablet)
Study: 8927195
Drug: Anti-stress therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-stress therapy
Study: 1624155
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride capsules
Study: 368231
Drug: Glucose electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose electrolyte solution
Study: 1624155
Drug: Glucose polymer
Normalized name: glucose polymers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose polymer solution
Study: 12077570
Drug: Adenosine treatment
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine treatment
Study: 8545744
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of 2,400 mg of hypoxoside (4 capsules 3 times daily for 11 days)
Study: 2253931
Drug: Lactitol (36.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactitol (36.3 g +/- 5 daily)
Study: 2253931
Drug: Lactulose (38.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (38.2 g +/- 19 daily)
Study: 30910563
Drug: Usual upper
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual upper limb therapy 5 days a week for 5 weeks
Study: 26144895
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg HB vaccine in Group C
Study: 22509319
Drug: MTZ-Clind (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTZ-Clind (oral metronidazole 400 mg bid + 2% vaginal clindamycin-cream)
Study: 22509319
Drug: MTZ-Prob (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTZ-Prob (oral metronidazole 400 mg bid + Lactobacillus acidophilus vaginal-probiotic)
Study: 22509319
Drug: MTZ-Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTZ-Placebo (oral metronidazole 400 mg bid + placebo)
Study: 15385356
Drug: Cisatracurium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.2 mg/kg based on real body weight (RBW) in Group I (n = 10)
Study: 2337059
Drug: Overall Olsalazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall Olsalazine treatment
Study: 10328033
Drug: 720 mg
Normalized name: pancreatin 720 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 720 mg trimethoprim plus 3,600 mg sulfamethoxazole
Study: 10328033
Drug: 3.5 g
Normalized name: Calcium 760 MG/3.5 GM Oral Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 g ampicillin plus 1 g probenecid